iBio has announced that the U.S. Patent and Trademark Office has allowed patent application 13/445,492, “Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides.”

The patent’s allowed fundamental composition of matter and method claims grant important exclusivity over new, modified carrier molecules derived from the company’s proprietary iBioModulator system and their use with one or more target proteins or antigens. These new carriers offer new capabilities for creating high-performance vaccine candidates for difficult disease targets. The iBioModulator system was developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology, the company’s research collaborator.

Shown to significantly modify the immune response to a vaccine in two keys ways, the iBioModulator platform increases the strength of the initial immune response to a vaccine antigen (as measured by antibody titer) and also extends the duration of the immune response, lowering vaccine antigen requirements or enabling fewer doses to establish prolonged immunity. Significant value is added to a vaccine by this generation of a stronger immune response and longer-term protection without booster inoculations, as it reduces overall costs and logistical difficulties while effectively reaching a higher proportion of the target population.

iBio uses the iBioModulator platform – including the technology covered by this new patent – for the biopharmaceutical products developed with its proprietary iBioLaunch plant-based protein expression system. The company also provides the benefits of its iBioModulator platform through licenses to product developers who use the iBioLaunch system or other protein expression systems.

For more information, visit www.ibioinc.com

Let us hear your thoughts below: